Category: Impacting News

The US FDA Approved United Therapeutics Product Tyvaso DPI™ for PAH and ILD

United Therapeutics Approval for Tyvaso DPI™ The US FDA approved United Therapeutics ( UTHR ) product Tyvaso DPI™ (treprostinil) inhalation powder for pulmonary arterial hypertension ( PAH ) and pulmonary hypertension associated with interstitial lung disease ( ILD ) to...

Read More

May 27, 2022

0

Pliant Therapeutics: Positive Long-Term Data from INTEGRIS-PSC Phase 2a Trial of Bexotegrast

Pliant Therapeutics Pliant Therapeutics is a late-stage biopharmaceutical company focusing on the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast ( PLN-74809 ), is an oral, small molecule, dual selective inhibitor...

Read More

July 16, 2024

0

Ionis Pharmaceuticals Announces Positive Detailed Results from the HALOS Study of ION582

Ionis Pharmaceuticals in the NEWS Yesterday,  July 22, 2024,  Ionis Pharmaceuticals ( IONS ) announced positive results from the completed multiple ascending dose ( MAD ) portion of the Phase 1/2 open-label study of ION582 in people with Angelman syndrome...

Read More

July 23, 2024

0

Bristol-Myers Squibb: Deucravacitinib Demonstrates Promising Results in Treating Systemic Lupus Erithematosus

Bristol-Myers Squibb Product Deucravacitinib Bristol-Myers Squibb ( BMY ) product deucravacitinib has demonstrated positive results from the Phase 2 PAISLEY study in comparison to placebo in patients with moderate to severe systemic lupus erythematosus ( SLE ). The study met...

Read More

June 2, 2022

0

Viking Therapeutics Reports Promising News

Viking Therapeutics Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials.  Viking's research and development activities leverage...

Read More

July 25, 2024

0

Inflation and the Stock Market. ASCO: Different Data's Presentations Promising to Defeat Solid Tumors

Inflation and the Stock Market Inflation, which we were told was but a temporary passing phenomenon, has reached its maximum peak in four decades. We must not get anxious about this inflation, a well-known enemy to the economy and a...

Read More

June 10, 2022

0

Verrica Pharmaceuticals: Collaboration and License Agreements for the Treatment of Skin Diseases Other Than Molluscum Contagiosum

Verrica Pharmaceuticals Verrica Pharmaceuticals’ ( VRCA ) product YCANTH ( cantharidin ) is the only commercially available treatment approved by the FDA for the treatment of adults and pediatric patients two years of age and older with Molluscum Contagiosum. Molluscum...

Read More

May 16, 2024

0

Anavex Life Sciences: Phase IIb/III Trial Results of Blarcamesine Presented at Alzheimer's Association Conference 

Anaves Life Sciences Trial Results of Blarcamesine Anavex Life Sciences ( AVXL ) presented comprehensive results from a Phase IIb/III study showing that blarcamesine (ANAVEX®2-73), once daily orally, significantly slowed clinical decline in people with early Alzheimer's disease ( AD...

Read More

July 29, 2024

0

Health Canada Approved Amylyx Pharmaceuticals' Product ALBRIOZA for Amyotrophic Lateral Sclerosis

The Great News from Amylyx Pharmaceuticals On Jun. 13, 2022, Amylyx Pharmaceuticals ( AMLX ) announced that Health Canada has approved ALBRIOZA (sodium phenylbutyrate and ursodoxicoltaurine), with conditions, for amyotrophic lateral sclerosis ( ALS ). The important thing to learn...

Read More

June 23, 2022

0

Adaptimmune Therapeutics: A First Approved Treatment of Unresectable or Metastatic Synovial Sarcoma

Adaptimmune Therapeutics Adaptimmune Therapeutics plc ( ADAP ) announced that the U.S. FDA has accelerated the approval of TECELRA® for the treatment of adults with unresectable or metastatic synovial sarcoma who received prior chemotherapy, and are  HLA-A*02:01P, -A*02:02P, -A*02:03P, or...

Read More

August 2, 2024

0

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0